Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers.

ABSTRACT:

Background

Molecular components in blood, such as proteins, are used as biomarkers to detect or predict disease states, guide clinical interventions and aid in the development of therapies. While multiplexing proteomics methods promote discovery of such biomarkers, their translation to clinical use is difficult due to the lack of substantial evidence regarding their reliability as quantifiable indicators of disease state or outcome. To overcome this challenge, a novel orthogonal strategy was developed and used to assess the reliability of biomarkers and analytically corroborate already identified serum biomarkers for Duchenne muscular dystrophy (DMD). DMD is a monogenic incurable disease characterized by progressive muscle damage that currently lacks reliable and specific disease m

SUBMITTER: Johansson C 

PROVIDER: S-EPMC10258980 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature